Esperion Therapeutics’ (ESPR) “Market Outperform” Rating Reiterated at JMP Securities
JMP Securities reissued their market outperform rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $4.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $7.00. ESPR has been the subject of several other […]
JMP Securities reissued their market outperform rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $4.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $7.00. ESPR has been the subject of several other […]
